ATE337016T1 - Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen - Google Patents

Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Info

Publication number
ATE337016T1
ATE337016T1 AT00931720T AT00931720T ATE337016T1 AT E337016 T1 ATE337016 T1 AT E337016T1 AT 00931720 T AT00931720 T AT 00931720T AT 00931720 T AT00931720 T AT 00931720T AT E337016 T1 ATE337016 T1 AT E337016T1
Authority
AT
Austria
Prior art keywords
orally administered
bioavailability
compositions
increase
pharmaceutical compounds
Prior art date
Application number
AT00931720T
Other languages
English (en)
Inventor
Johannes Henricus Ma Schellens
Alfred Hermanus Schinkel
Original Assignee
Cancer Res Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Ventures Ltd filed Critical Cancer Res Ventures Ltd
Application granted granted Critical
Publication of ATE337016T1 publication Critical patent/ATE337016T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00931720T 1999-05-17 2000-05-17 Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen ATE337016T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1012066 1999-05-17
NL1012481 1999-06-30

Publications (1)

Publication Number Publication Date
ATE337016T1 true ATE337016T1 (de) 2006-09-15

Family

ID=26642978

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00931720T ATE337016T1 (de) 1999-05-17 2000-05-17 Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
AT06117838T ATE484295T1 (de) 1999-05-17 2000-05-17 Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06117838T ATE484295T1 (de) 1999-05-17 2000-05-17 Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Country Status (10)

Country Link
US (2) US7030132B2 (de)
EP (2) EP1749540B1 (de)
AT (2) ATE337016T1 (de)
AU (1) AU4955200A (de)
CY (1) CY1105795T1 (de)
DE (2) DE60045114D1 (de)
DK (1) DK1189637T3 (de)
ES (1) ES2270834T3 (de)
PT (1) PT1189637E (de)
WO (1) WO2000069390A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP1749540B1 (de) * 1999-05-17 2010-10-13 Cancer Research Ventures Limited Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
HU0100947D0 (en) * 2001-03-02 2001-05-28 Solvo Kft Screening system based on expression of abcg2 half transporter protein in an expression system free of other abc-transporters, abcg2 homodimers
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers
AU2005269052A1 (en) * 2004-07-01 2006-02-09 The Netherlands Cancer Institute Combination comprising a BCRP inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
US8518022B2 (en) 2004-08-27 2013-08-27 Medimetrics Personalized Drug Delivery, Inc. Electronically and remotely controlled pill and system for delivering at least one medicament
JP2008521794A (ja) * 2004-11-29 2008-06-26 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 少なくとも一の薬剤を輸送するための、少なくとも一のセンサを有する電子制御式の錠剤およびシステム
WO2006065125A1 (en) * 2004-12-16 2006-06-22 Het Nederlands Kanter Instituut Means and methods for determining and/or influencing transportation
WO2009083042A1 (en) * 2007-12-31 2009-07-09 Olaf Van Tellingen Methods and means for the treatment of cancer
CN101945613B (zh) * 2008-02-18 2014-08-13 皇家飞利浦电子股份有限公司 为患者用药
US8990018B2 (en) * 2008-03-31 2015-03-24 MEDIMETRICS Personalized Drug Delivery B.V. Method of preparing a swallowable capsule comprising a sensor
CA2975841C (en) 2008-04-30 2021-05-25 Siemens Medical Solutions Usa, Inc. Substrate based pet imaging agents
EP2303361B1 (de) * 2008-06-19 2015-02-25 Medimetrics Personalized Drug Delivery B.V. Kapsel zur abgabe von pulverförmigem medikament in den verdauungstrakt
WO2009156919A1 (en) * 2008-06-25 2009-12-30 Koninklijke Philips Electronics N.V. Electronic pill comprising a plurality of medicine reservoirs
EP2464414B1 (de) 2009-08-12 2013-06-12 Medimetrics Personalized Drug Delivery B.V. Wirkstofffreisetzungsvorrichtung mit komprimierbarem wirkstoffreservoir
CN106432490B (zh) 2016-09-14 2020-01-07 北京大学 一种abcg2单克隆抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201084A (en) 1982-06-25 1985-10-11 New Zealand Dev Finance 4-carboxamidoacridine derivatives and pharmaceutical compositions containing such
HUT68856A (en) * 1991-01-11 1995-08-28 Glaxo Lab Sa Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions
DE69310367T2 (de) 1992-07-10 1997-08-14 Glaxo Lab Sa Anilide-derivate
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
WO1996011007A1 (en) 1994-10-05 1996-04-18 Glaxo Wellcome Inc. Parenteral pharmaceutical compositions containing gf120918a
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
GB9710612D0 (en) * 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
DK0994706T3 (da) 1997-05-27 2006-03-06 Ivax Research Inc Præparater til oral indgivelse af taxaner og anvendelse deraf
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6313277B1 (en) * 1998-02-05 2001-11-06 University Of Maryland, Baltimore Breast cancer resistance protein (BCRP) and the DNA which encodes it
IL134592A0 (en) 1998-06-18 2001-04-30 Univ George Washington Compositions comprising camptothecin compounds for the treatment of cancer with reduced side effects
DK1102594T3 (da) 1998-08-05 2002-08-26 Aventis Pharma Sa Anvendelse af natriumchlorid til nedsættelse af den gastrointestinale toxicitet af derivater af camptothecin
EP1749540B1 (de) * 1999-05-17 2010-10-13 Cancer Research Ventures Limited Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
US6521635B1 (en) * 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives

Also Published As

Publication number Publication date
US20020128282A1 (en) 2002-09-12
DE60045114D1 (de) 2010-11-25
CY1105795T1 (el) 2011-02-02
EP1749540A2 (de) 2007-02-07
DE60030283T2 (de) 2007-09-20
ES2270834T3 (es) 2007-04-16
US20060128743A1 (en) 2006-06-15
DK1189637T3 (da) 2006-12-11
WO2000069390A2 (en) 2000-11-23
ATE484295T1 (de) 2010-10-15
EP1749540B1 (de) 2010-10-13
US7030132B2 (en) 2006-04-18
WO2000069390A3 (en) 2001-12-13
EP1749540A3 (de) 2007-05-30
PT1189637E (pt) 2007-01-31
DE60030283D1 (de) 2006-10-05
AU4955200A (en) 2000-12-05
EP1189637B1 (de) 2006-08-23
EP1189637A2 (de) 2002-03-27

Similar Documents

Publication Publication Date Title
ATE337016T1 (de) Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
CY1121133T1 (el) Τοπικα εφαρμοσιμο φαρμακευτικο παρασκευασμα
ATE339954T1 (de) Kombinationen von formoterol und tiotropium-salz
NZ324801A (en) Oral pharmaceutical dosage form containing taxol or etoposide derivatives and a bioenhancer compound
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
CY1118873T1 (el) Φαρμακευτικη δοσολογικη μορφη μιας φαρμακευτικα αποδεκτης ενωσης διαλυτοποιησης
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
DE69526428D1 (de) Verfahren zur erhöhung der bioverfügbarkeit oraler arzneimittel
ATE292453T1 (de) Antivirale arznei
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
EP1574215A4 (de) Feste arznei zur oralen verabreichung
DE60124144D1 (de) Pharmazeutische zusammenstellungen zur verstärkung der artzneimitteleffekte
EA199901116A1 (ru) Композиция, включающая 5-[4-[2-(n-метил-n-2-пиридил)-амино)этокси]бензил]тиазолидин-2,4-дион
ITMI992736A0 (it) Composizioni farmaceutiche per la somministrazione localizzata nel cav o orale di farmaci antiinfiammatori non stereoidei utili per la terapi
EA200602199A1 (ru) Композиции, содержащие глюкозаминогликан и нестероидное противовоспалительное средство
IT1248669B (it) Derivato di idrossiprolina, sua preparazione e composizioni farmaceutiche che lo contengono
GT200100223A (es) Composiciones hidroliticamente inestables.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1189637

Country of ref document: EP